Research Analysts Issue Forecasts for AQST FY2024 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a report issued on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of ($0.45) for the year. Cantor Fitzgerald has a “Overweight” rating and a $17.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.47) per share.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter in the prior year, the firm posted ($0.03) earnings per share.

AQST has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday. Leerink Partners raised their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, JMP Securities reiterated a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Stock Performance

AQST opened at $3.65 on Thursday. The company’s 50-day simple moving average is $4.71 and its two-hundred day simple moving average is $4.07. Aquestive Therapeutics has a 52-week low of $1.84 and a 52-week high of $6.23. The stock has a market capitalization of $332.80 million, a P/E ratio of -8.11 and a beta of 2.62.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics in the third quarter worth approximately $995,000. Blue Owl Capital Holdings LP increased its holdings in shares of Aquestive Therapeutics by 30.3% in the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after purchasing an additional 265,000 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $594,000. Wellington Management Group LLP purchased a new stake in Aquestive Therapeutics during the third quarter valued at $922,000. Finally, Chartwell Investment Partners LLC purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $535,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.